Abstract
A new class of designer drugs can reprogram gene expression by linking a transcription factor that silences genes involved in cell death with an epigenetic regulator that stimulates gene activity. A prototype molecule showed robust potency in flipping the function of BCL6, a protein that supports lymphoma cell proliferation, offering a promising therapeutic approach to combat cancer cell growth.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
